Screening		Days					Treatment interruption – follow-up
Time Window	± 7 days		± 2 days (except D25 ± 4)					± 2 days
Days (D)	D-21	D0	D7	D14	D21	D25	D28	Twice weekly for 3 weeks	Every week till VR	ART reintroduction visit	FU visit(s)***
Informed consent	X
Check of IN/EX criteria	X	X
Physical examination	X	X	X	X	X	X	X	X	X	X	X
Body weight (kg)	X	X	X	X	X	X	X	X	X	X	X
Height measurement (cm)	X
Medical history	X
Telephone calls to participants		Day 3 and 5
Serology for HBV, HCV, HIV	X
Haematology and biochemistry	X	X	X	X	X	X	X		X	X	X*****
CD4 and CD8 count	X	X	X	X	X	X	X	X	X	X	X
Urinalysis	X	X	X	X	X	X	X	X****	X	X
Blood pregnancy test	X
Urine pregnancy test	X	X	X	X	X	X	X		X	X
Vital signs	X	X	X	X	X	X	X		X	X
ECG (12 lead)	X	X	X				X			X
DRV/RTV or COBI prescription	X	X	X	X	X	X	X			X	X
ABX464/placebo treatment dispensation and patient diary review		X	X	X	X	X	X
Blood samples–drug PK		X*	X*	X*	X*	X**
Blood samples for viral load and miRNA	X	X	X	X	X	X	X	X	X	X	X
HIV-1 genotyping										X
Leukapheresis (optional)	X									X
Blood samples for reservoir assessment •HIV-1 DNA •TILDA	X	X					X			X X
Adverse events recording		X	X	X	X	X	X		X	X	X

DRV: darunavir; RTV: ritonavir; COBI: cobiscistat; FU: follow-up; VR: viral rebound.

*: pre DRV/RTV or DRV/COBI morning dose

**: pre DRV/RTV or DRV/COBI morning dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 h post-dose (hospitalisation was not required)

***: every 14 days till undetectable viral load

****: urinalysis performed once a week

*****: only biochemistry required and for at least 28 days after treatment interruption